Lyka Labs Ltd's Q4FY25 Quarter Results
- 27 May 2025
Result Summary
- Lyka Labs Ltd reported a 18.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 23.8%.
- Its expenses for the quarter were down by 4.3% QoQ and up 17.6% YoY.
- The net profit decreased 177.1% QoQ and decreased 30.3% YoY.
- The earnings per share (EPS) of Lyka Labs Ltd declined at 3.8 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 28.06 | 34.62 | 22.67 | -18.9% | 23.8% |
Total Expenses | 29.71 | 31.04 | 25.26 | -4.3% | 17.6% |
Profit Before Tax | -1.63 | 3.57 | -3.00 | -145.7% | -45.7% |
Tax | 0.46 | 0.87 | 0.00 | -47.1% | - |
Profit After Tax | -2.09 | 2.71 | -3.00 | -177.1% | -30.3% |
Earnings Per Share | -3.80 | 0.80 | -1.10 | -575.0% | 245.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lyka Labs Ltd is a pharmaceutical company that primarily engages in the manufacturing and marketing of proprietary pharmaceutical formulations. The company operates within the healthcare industry, focusing on both domestic and international markets. As of the latest update, there are no specific major developments available in the data provided that pertain to Lyka Labs Ltd. The company’s portfolio typically includes a range of therapeutic segments, such as dermatology, respiratory, and other specialty products. Without additional information, it is not possible to provide further recent developments or strategic initiatives that Lyka Labs Ltd may have undertaken.
Revenue
In Q4FY25, Lyka Labs Ltd reported a total income of ₹28.06 crores, a decrease of 18.9% quarter-over-quarter from ₹34.62 crores in Q3FY25. However, on a year-over-year basis, there was an increase of 23.8% compared to the ₹22.67 crores in Q4FY24. This indicates variability in the company’s revenue stream over the quarters, with a notable improvement compared to the same quarter in the previous year. Such fluctuations could reflect changes in sales volumes, pricing strategies, or market demand for the company's products.
Profitability
The company’s profitability metrics for Q4FY25 show a challenging quarter. Profit Before Tax (PBT) was negative at ₹-1.63 crores, down significantly from a positive ₹3.57 crores in Q3FY25, marking a quarter-over-quarter decline of 145.7%. Year-over-year, the PBT improved from a loss of ₹-3.00 crores in Q4FY24, representing a 45.7% improvement. Profit After Tax (PAT) was also negative at ₹-2.09 crores in Q4FY25, a sharp decline from the ₹2.71 crores in Q3FY25, with a corresponding quarter-over-quarter change of -177.1%. Compared to Q4FY24, the PAT improved by 30.3% from a loss of ₹-3.00 crores. Earnings Per Share (EPS) reflected this trend, recording ₹-3.80 in Q4FY25 compared to ₹0.80 in Q3FY25, resulting in a 575.0% decline quarter-over-quarter. Year-over-year, EPS saw a significant increase from ₹-1.10 in Q4FY24, a 245.5% rise.
Operating Metrics
Lyka Labs Ltd’s operating expenses in Q4FY25 totaled ₹29.71 crores, which represented a decrease of 4.3% from ₹31.04 crores in Q3FY25. Year-over-year, total expenses increased by 17.6% from ₹25.26 crores in Q4FY24, which suggests changes in operational efficiency or cost structures over the year. The tax expense for Q4FY25 was ₹0.46 crores, showing a reduction of 47.1% from ₹0.87 crores in Q3FY25. There is no year-over-year comparison available for the tax expense as it was not recorded in Q4FY24. These operating metrics provide insight into the company's cost management strategies and how these affect the overall financial performance across different periods.